keyword
MENU ▼
Read by QxMD icon Read
search

rituximab and lymphoma relapse

keyword
https://www.readbyqxmd.com/read/29678710/pediatric-type-follicular-lymphoma-in-the-dura-a-case-report-and-literature-review
#1
Junya Yamaguchi, Seiichi Kato, Eri Iwata, Kosuke Aoki, Ryusuke Kabeya, Atsushi Natsume, Toshihiko Wakabayashi
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a relatively common tumor of the central nervous system. Although PCNSLs generally arise from the parenchyma, lymphomas arising primarily from the dura are termed dural lymphomas (DL). Mucosa-associated lymphoid tissue is the most unique histological feature of DL. Due to its rarity, clinical characteristics and treatments for DL have not been fully elucidated to date. CASE DESCRIPTION: A 31-year-old man with no past medical history presented with numbness in his left upper limb...
April 17, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29674440/lenalidomide-in-pretreated-mantle-cell-lymphoma-patients-an-italian-observational-multicenter-retrospective-study-in-daily-clinical-practice-the-lenamant-study
#2
Vittorio Stefoni, Cinzia Pellegrini, Alessandro Broccoli, Luca Baldini, Monica Tani, Emanuele Cencini, Amalia Figuera, Michela Ansuinelli, Elisa Bernocco, Maria Cantonetti, Maria Christina Cox, Filippo Ballerini, Chiara Rusconi, Carlo Visco, Luca Arcaini, Angelo Fama, Roberto Marasca, Stefano Volpetti, Alessia Castellino, Catello Califano, Marina Cavaliere, Guido Gini, Anna Marina Liberati, Gerardo Musuraca, Anna Lucania, Giuseppina Ricciuti, Lisa Argnani, Pier Luigi Zinzani
BACKGROUND: Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options for relapsed MCL are limited, although several single agents have been studied. Lenalidomide is available in Italy for patients with MCL based on a local disposition of the Italian Drug Agency. SUBJECTS, MATERIALS, AND METHODS: An observational retrospective study was conducted in 24 Italian hematology centers with the aim to improve information on effectiveness and safety of lenalidomide use in real practice...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29663029/yttrium-90-ibritumomab-tiuxetan-zevalin-followed-by-beam-z-beam-conditioning-regimen-and-autologous-stem-cell-transplantation-asct-in-relapsed-or-refractory-high-risk-b-cell-non-hodgkin-lymphoma-nhl-a-single-institution-italian-experience
#3
Chiara Ciochetto, Barbara Botto, Roberto Passera, Marilena Bellò, Giulia Benevolo, Carola Boccomini, Alessia Castellino, Annalisa Chiappella, Roberto Freilone, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Gianni Bisi, Umberto Vitolo
Chemo-refractory NHL has a very poor outcome; the addiction of RIT to salvage regiment pre ASCT had recently demonstrated promising results.We performed a retrospective sequential study to determine the feasibility of standard Zevalin with BEAM in high-risk relapse/refractory NHL. A matched cohort analysis with a group treated with standard BEAM without Zevalin was performed as secondary endpoint. Between October 2006 and January 2013, 37 NHL patients at high risk for progression or early (< 1 year) or multiple relapses were treated with Z-BEAM and ASCT after R-DHAP or R-ICE as salvage therapy...
April 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29623179/co-expression-of-myc-and-bcl2-predicts-poorer-outcomes-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-with-r-ice-and-intent-to-transplant
#4
Joshua Allen, Ana Lucia Ruano Mendez, Lisa Rybicki, Yazeed Sawalha, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Mitchell R Smith, Eric D Hsi, Brian T Hill
Diffuse large B-cell lymphoma (DLBCL) with co-expression of MYC and BCL2 protein by immunohistochemistry (IHC) - that is, double-expresser lymphoma (DEL) - is associated with poor outcomes after standard frontline therapy. Less is known about the prognostic impact of DEL in patients with relapsed/refractory disease treated with salvage therapy and autologous stem cell transplantation (ASCT). We analyzed the outcomes of 167 patients with relapsed/refractory DLBCL treated with R-ICE (rituximab, ifosfamide, carboplatin and etoposide), of whom 111 patients (66%) underwent ASCT...
April 2018: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29623003/the-diving-bell-and-the-butterfly-revisited-a-fatal-case-of-locked-in-syndrome-in-a-man-with-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-not-otherwise-specified
#5
Jacqueline N Poston, Russell Dorer, David M Aboulafia
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant of DLBCL. The natural history of this subtype is poorly understood. Incomplete literature in the era of rituximab suggests that patients with EBV-positive DLBCL have similar outcomes to patients with EBV-negative DLBCL when treated with rituximab and anthracycline-based chemotherapy regimens; however, there are few prospective studies on this subtype and little is known about the risk of central nervous system (CNS) relapse with EBV-positive DLBCL...
2018: Clinical Medicine Insights. Blood Disorders
https://www.readbyqxmd.com/read/29619501/bendamustine-plus-rituximab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-analysis
#6
Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Jin Seok Kim, Won-Sik Lee, Sung Yong Oh, Yong Park, Sung-Yong Kim, Mark Hong Lee, Ho Sup Lee, Young Rok Do
Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea...
April 4, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29610968/impact-of-hematopoietic-stem-cell-transplantation-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
#7
Satoshi Yamasaki, Dai Chihara, Sung-Won Kim, Koji Izutsu, Kouji Iwato, Takahiro Fukuda, Naoyuki Uchida, Itsuto Amano, Hideyuki Nakazawa, Junya Kuroda, Hisako Hashimoto, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Junji Suzumiya, Ritsuro Suzuki
Rituximab has been shown to improve outcomes in patients with B-cell lymphoma. However, patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) still have a poor prognosis, and the choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains controversial in these patients. We retrospectively analyzed the risk factors for outcomes in 162 R/R MCL patients who received autologous (n = 111) or allogeneic (n = 51) HCT between 2004 and 2014...
April 2, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29609086/primary-central-nervous-system-hodgkin-lymphoma-like-post-transplant-lymphoproliferative-disorder
#8
Yusuke S Hori, Keina Nagakita, Yuki Ebisudani, Mizuho Aoi, Toru Fukuhara, Yoko Shinno
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a rare condition occurring after organ transplantation. PTLD comprises four subtypes, of which Hodgkin lymphoma (HL)-type and HL-like type (currently included in polymorphic type) account for only about 1%-3% of cases. Primary central nervous system PTLD is also rare, and most cases are Epstein-Barr virus-positive, B-cell PTLD, while no case of HL-like PTLD has yet been documented. CASE DESCRIPTION: We present a 43-year-old woman who underwent kidney transplantation for IgA nephropathy 14 years previously, and who presented to our Emergency Department with a chief complaint of seizure...
March 30, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29596904/a-single-arm-phase-ii-trial-of-lenalidomide-in-relapsing-or-refractory-primary-cutaneous-large-b-cell-lymphoma-leg-type
#9
Marie Beylot-Barry, Diane Mermin, Aline Maillard, Reda Bouabdallah, Nathalie Bonnet, Anne-Bénédicte Duval-Modeste, Laurent Mortier, Saskia Ingen-Housz-Oro, Caroline Ram-Wolff, Stéphane Barete, Stéphane Dalle, Eve Maubec, Gaelle Quereux, Isabelle Templier, Martine Bagot, Florent Grange, Pascal Joly, Béatrice Vergier, Pierre-Julien Vially, Audrey Gros, Anne Pham-Ledard, Eric Frison, Jean-Philippe Merlio
While the combination of rituximab and polychemotherapy has improved prognosis of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), advanced age of patients limits therapeutic options in relapsing/refractory cases. A multicenter single-arm phase II trial was conducted to assess benefit and safety of lenalidomide in refractory/relapsing PCDLBCL, LT. Primary endpoint was the 6-month overall response rate (ORR). Secondary endpoints were 12-month ORR, overall and specific survival, duration of response, progression-free survival (PFS), safety and identification of prognostic factors...
March 26, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29595951/amplification-of-cd20-crosslinking-in-rituximab-resistant-b-lymphoma-cells-enhances-apoptosis-induction-by-drug-free-macromolecular-therapeutics
#10
Lian Li, Jiyuan Yang, Jiawei Wang, Jindrich Kopecek
Although the CD20-targeted monoclonal antibody rituximab (RTX) has revolutionized the therapeutic landscape for B-cell malignancy, relapsed and refractory disease due to RTX resistance continue to constitute major challenges, illustrating the need for better therapies. Here, we apply drug-free macromolecular therapeutics (DFMT) that amplifies CD20 crosslinking to enhance apoptosis in RTX resistant cells. Bispecific engager (anti-CD20 Fab' conjugated with oligonucleotide1) pretargets CD20 and the deletion of Fc-region minimizes its premature endocytosis in resistant cells that rapidly internalize and consume CD20/RTX complexes...
March 29, 2018: ACS Nano
https://www.readbyqxmd.com/read/29577096/intravitreal-rituximab-for-the-treatment-of-a-secondary-intraocular-relapse-of-a-large-b-cell-lymphoma
#11
Jose J Echegaray, Stephanie Llop, Melissa Sepulveda, Roman Velez-Rosario, Noel Perez, Armando L Oliver
Purpose: To report a rare case of secondary intraocular lymphoma treated with intravitreal rituximab, following pars plana vitrectomy. Observations: A 74-year-old female with history of parotid gland large B-cell lymphoma presented bilateral intraocular recurrence 10 years after the onset of the primary malignancy. Systemic work-up including PET/CT Scan, bone marrow biopsy, brain MRI and CSF analysis were unremarkable, and the patient declined to undergo systemic chemotherapy...
March 2018: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29542329/treating-relapsed-follicular-lymphoma
#12
Thomas Erblich, Silvia Montoto
Advanced follicular lymphoma (FL) remains an incurable disease, at least with conventional therapy. Despite the long remission and disease-free periods that can be currently achieved with treatment, the disease will ultimately relapse in most of the patients. Areas covered: This article reviews the current spectrum of therapies for patients with relapsed FL in the rituximab area. It will revisit current therapies, approaches to therapeutic decision making and novel agents under investigation. Expert commentary: At present, rituximab or second generation anti-CD20 antibodies either as single agent or in combination with chemotherapy, anti-CD20 maintenance therapy and stem cell transplant remain effective treatment options for relapsed patients...
March 20, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29533000/ibrutinib-versus-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-a-randomized-open-label-phase-3-study
#13
Xiaojun Huang, Lugui Qiu, Jie Jin, Daobin Zhou, Xiequn Chen, Ming Hou, Jianda Hu, Yu Hu, Xiaoyan Ke, Junmin Li, Yingmin Liang, Ting Liu, Yue Lv, Hanyun Ren, Aining Sun, Jianmin Wang, Chunting Zhao, Mariya Salman, Steven Sun, Angela Howes, Jingzhao Wang, Peng Wu, Jianyong Li
In the Asia-Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Rituximab is widely used in this setting when purine analog-based therapies are not appropriate. We evaluated the efficacy and safety of ibrutinib compared with rituximab in a randomized, open-label phase 3 study in predominantly Asian patients with relapsed/refractory CLL/SLL. Patients (N = 160) were randomly assigned 2:1 to receive 420 mg ibrutinib (n = 106) until disease progression (PD) or unacceptable toxicity or up to six cycles of rituximab (n = 54)...
March 13, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29532919/impact-of-novel-therapies-for-mantle-cell-lymphoma-in-the-real-world-setting-a-report-from-the-uk-s-haematological-malignancy-research-network-hmrn
#14
Alexandra Smith, Eve Roman, Simon Appleton, Debra Howell, Rod Johnson, Cathy Burton, Russell Patmore
The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether the effects observed in clinical trials have translated into the real-world setting. To investigate this, we examined first-line and relapsed/refractory (RR) disease management in 335 MCL patients diagnosed between 2004 and 2015 in an established population-based patient cohort, along with data on demographic, diagnostic and prognostic factors...
March 13, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29521148/does-maintenance-therapy-have-a-role-in-mantle-cell-lymphoma-treatment
#15
Madeliene Parrott, Simon Rule
Mantle cell lymphoma (MCL) is a rare but often aggressive B-cell non-Hodgkin lymphoma (NHL). Initial therapy can achieve high response rates but invariably patients relapse and die from their disease. Incorporating a maintenance phase into the treatment strategy may prolong remission duration and ultimately prolong survival. Areas covered: The current literature incorporating a maintenance phase into treatment strategies for newly diagnosed and pre-treated MCL patients has been summarized. A literature search was performed using search terms 'mantle cell lymphoma', 'indolent NHL', 'maintenance', 'interferon', 'rituximab', 'lenalidomide', 'bortezomib' and 'ibrutinib'...
April 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29488576/-rectal-diffuse-large-b-cell-lymphoma-appearing-after-immunosuppression-for-ulcerative-colitis-report-of-one-case
#16
Rodrigo Quera, Lilian Flores, Daniela Simian, Udo Kronberg, María Teresa Vial, David Ladrón de Guevara, María José García-Rodríguez
Primary colorectal lymphoma is a rare form of presentation of gastrointestinal tract lymphomas. Inflammatory bowel disease and its treatment are risk factors for its development. We report a 47-year-old male patient with Ulcerative Colitis of two years of evolution, treated initially with azathioprine and later on with infliximab. Due to a relapse in symptoms after the second dose of infliximab, a new coloncoscopy was performed showing a rectal ulcerative lesion, corresponding to a large cell Non-Hodgkin's Lymphoma...
October 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29479962/cd20-expression-and-effects-on-outcome-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-after-treatment-with-rituximab
#17
Afshan Asghar Rasheed, Adeel Samad, Ahmed Raheem, Samina Ismail Hirani, Munira Shabbir- Moosajee
Introduction: Down regulation of CD20 expression has been reported in diffuse large B cell lymphoma (DLBCL)). Therefore, it is important to determine whether chemotherapy with rituximab induces CD20 down regulation and effects survival. Objectives: To determine the incidence of down regulation of CD20 expression in relapsed DLBCL after treatment with rituximab and to compare outcomes and assess pattern of relapse between CD20 negative and CD20 positive cases. Methodology: We retrospectively reviewed patients with relapsed DLBCL who received rituximab in the first line setting at Aga Khan University Hospital between January 2007 and December 2014...
February 26, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29477102/treatment-strategies-outcomes-and-prognostic-factors-in-291-patients-with-secondary-cns-involvement-by-diffuse-large-b-cell-lymphoma
#18
Tarec Christoffer El-Galaly, Chan Yoon Cheah, Mette Dahl Bendtsen, Grzegorz S Nowakowski, Roopesh Kansara, Kerry J Savage, Joseph M Connors, Laurie H Sehn, Neta Goldschmidt, Adir Shaulov, Umar Farooq, Brian K Link, Andrés J M Ferreri, Teresa Calimeri, Caterina Cecchetti, Eldad J Dann, Carrie A Thompson, Tsofia Inbar, Matthew J Maurer, Inger Lise Gade, Maja Bech Juul, Jakob W Hansen, Staffan Holmberg, Thomas S Larsen, Sabrina Cordua, N George Mikhaeel, Martin Hutchings, John F Seymour, Michael Roost Clausen, Daniel Smith, Stephen Opat, Michael Gilbertson, Gita Thanarajasingam, Diego Villa
PURPOSE: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited. METHODS: Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records...
February 21, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29476021/updated-results-of-rituximab-pre-and-post-beam-with-or-without-90yttrium-ibritumomab-tiuxetan-during-autologous-transplant-for-diffuse-large-b-cell-lymphoma
#19
Jad Chahoud, Dawen Sui, William D Erwin, Alison M Gulbis, Martin Korbling, Mingzhi Zhang, Sairah Ahmed, Gheath Alatrash, Paolo Anderlini, Stefan O Ciurea, Betul Oran, Luis Fayad, Roland L Bassett, Elias Jabbour, L Jeffrey Medeiros, Homer A Macapinlac, Ken H Young, Issa F Khouri
PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). EXPERIMENTAL DESIGN: Patients were enrolled on three consecutive phase 2 clinical trials. Patients received two doses of rituximab (375 mg/m2 and 1000 mg/m2) during mobilization of stem cells, followed by 1000 mg/m2 on days +1 and +8 after ASCT with R-BEAM or 90YIT-R-BEAM (90YIT dose of 0...
February 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29473343/central-nervous-system-relapse-in-patients-over-80-years-with-diffuse-large-b-cell-lymphoma-an-analysis-of-two-lysa-studies
#20
Aurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, Jean-François Emile, Vincent Delwail, Nicolas Mounier, Corinne Haioun, Aurore Perrot, Olivier Fitoussi, Diane Lara, Richard Delarue, Marc André, Fritz Offner, Hervé Ghesquières, Laurent Pascal, Carole Soussain, Julien Lazarovici, Jean-Marc Schiano, Philippe Gaulard, Hervé Tilly, Catherine Thieblemont
CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy...
February 23, 2018: Cancer Medicine
keyword
keyword
114416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"